| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Apomorphine hydrochloride 2 mg sublingual tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing precisely apomorphine hydrochloride 3 milligram/1 each conventional release sublingual tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| médicaments utilisés pour traiter l'hyperuricémie |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing rasburicase (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Rasburicase 1.5mg powder and solvent for infusion vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing potassium iodate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Potassium iodate 85 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Ipecac 7mg syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Nalmefene hydrochloride 1mg/mL injection solution ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Nalmefene hydrochloride 100mcg/mL injection solution ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Fomepizole 1g/mL injection solution vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Tiopronin 100 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Succimer 1mg/vial injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Dexrazoxane hydrochloride 250mg/vial powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Dexrazoxane hydrochloride 500mg/vial powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing precisely succimer 100 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Cellulose sodium phosphate 2.5g powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Naloxone hydrochloride 400mcg/mL injection solution ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Naloxone hydrochloride 1mg/mL injection solution ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Naloxone hydrochloride 20mcg/mL injection solution ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Protamine sulfate 250mg/10mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Sevelamer hydrochloride 800mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Sevelamer hydrochloride 400 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Calcium 667mg gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Cysteamine bitartrate 50mg capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Cysteamine bitartrate 150mg capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Sodium polystyrene sulfonate 4.1meq/g powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Sodium polystyrene sulfonate 100% powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Sodium fluoride 1.1% cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing precisely naloxone hydrochloride 500 microgram and pentazocine hydrochloride 50 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Naloxone hydrochloride 2mg/2mL prefilled syringe |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Sevelamer 800mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Digoxin specific antibody 38mg powder for injection solution vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Nalmefene hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing succimer (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing tiopronin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing activated charcoal (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing methionine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Dexrazoxane hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Mesna 1g injection solution 20mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Mesna 200mg injection solution 2mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Flumazenil 0.1mg/mL injection solution 10mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Mesna 1g injection solution 10mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Mesna 400mg/amp injection solution 4mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Flumazenil 0.1mg/mL injection solution 5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing naloxone hydrochloride and pentazocine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Pralidoxime chloride 1g/20mL powder for injection 20mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Chlorhexidine gluconate+sodium nitrite 0.5/0.1% in 70% IMS solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Buprenorphine hydrochloride + naloxone hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Buprenorphine hydrochloride 2mg + naloxone hydrochloride 0.5mg sublingual tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Buprenorphine hydrochloride 8mg + naloxone hydrochloride 2mg sublingual tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Naloxone hydrochloride 2mg/2mL prefilled syringe |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing precisely sevelamer hydrochloride 800 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Rasburicase 7.5mg infusion (pdr for recon)+solvent |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing atropine and pralidoxime (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Atropine/pralidoxime two auto-injectors injection solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Atropine/pralidoxime single auto-injector solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Atropine 2.1mg/pralidoxime 600mg single auto-injector solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Atropine 2mg/pralidoxime 600mg two auto-injectors solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Naltrexone hydrochloride 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Naltrexone hydrochloride 100 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Sodium thiosulfate 12.5g/50mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Apomorphine hydrochloride 10mg/mL injection solution 3mL cartridge |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| anticorps spécifique de la digoxine 40mg, pour injection (poudre pour reconstitution) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Razoxane 125 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Cellulose sodium phosphate 300g/bottle powder for oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing pentetate zinc trisodium |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Calcium pentétate trisodique |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Pentetate calcium trisodium 200mg/mL injection solution 5mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Pentetate zinc trisodium 200mg/mL injection solution 5mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Phosphate binding preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing lanthanum carbonate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing precisely lanthanum carbonate 250 milligram/1 each conventional release chewable tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing precisely lanthanum (as lanthanum carbonate) 500 milligram/1 each conventional release chewable tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing razoxane (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing precisely sevelamer hydrochloride 800 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Flumazenil 0.1mg/mL injection solution 5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Gadoxetic acid (substance) |
Is a |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Chelation of cornea |
Direct substance |
False |
Chelating agent |
Inferred relationship |
Some |
1 |
| Apomorphine hydrochloride 50mg injection solution 10ml prefilled syringe |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing dexrazoxane (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Deferasirox (substance) |
Is a |
True |
Chelating agent |
Inferred relationship |
Some |
|
| Accidental chelating agent poisoning |
Causative agent (attribute) |
False |
Chelating agent |
Inferred relationship |
Some |
1 |
| Intentional chelating agent poisoning |
Causative agent (attribute) |
False |
Chelating agent |
Inferred relationship |
Some |
1 |
| Ammonia+ipecacuanha mixture |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing ammonia and ipecacuanha (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing polyvalent crotalidae antivenom (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing crotalidae polyvalent immune fab (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing precisely lanthanum (as lanthanum carbonate) 750 milligram/1 each conventional release chewable tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Lanthanum carbonate 1g chewable tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing ipecacuanha and sodium bicarbonate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing ammonium bicarbonate and ipecacuanha and sodium bicarbonate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing activated charcoal and magnesium hydroxide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Product containing citric acid and ipecacuanha (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Sodium polystyrene sulfonate 454g powder/bottle for suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Naltrexone-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Naltrexone-containing product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Naltrexone microspheres 380mg powder for injection solution vial + diluent |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Chelating agent |
Inferred relationship |
Some |
|
| Chelation of cornea |
Direct substance |
True |
Chelating agent |
Inferred relationship |
Some |
1 |
| Unithiol |
Is a |
True |
Chelating agent |
Inferred relationship |
Some |
|
| allergia ad agente chelante |
Causative agent (attribute) |
False |
Chelating agent |
Inferred relationship |
Some |
1 |
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]